Allergan’s Valuation Compared to Its Peers


Nov. 29 2016, Updated 2:25 p.m. ET

Allergan’s valuation

From an investor’s point of view, the two best valuation multiples used for valuing companies like Allergan are the forward PE (price-to-earnings) and EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiples, considering the relatively stable and visible nature of their earnings.

The above chart shows a comparison of actual and estimated EPS (earnings per share) over the last few quarters. The company missed analysts’ EPS estimates during 3Q16. It reported EPS of $3.22—compared to the estimated EPS of $3.58 for 3Q16.

Article continues below advertisement

Forward PE multiple

PE multiples represent what one share can buy for an equity investor. As of November 29, 2016, Allergan (AGN) was trading at a forward PE multiple of ~12.1x—compared to the industry average of 14.4x. Over the past year, the company’s forward PE multiple traded in the range of 13.2x–20.0x. The company is trading at a higher PE multiple than its competitors like Mylan (MYL), Perrigo (PRGO), and Lannett (LCI). They trade at 6.9x, 11.8x, and 7.1x, respectively.

Forward EV-to-EBITDA multiple

On a capital structure neutral and excess cash-adjusted basis, Allergan currently trades at ~10.2x, which is higher than the industry’s average of ~9.6x. Other competitors such as Perrigo, Mylan, and Lannett have forward EV-to-EBITDA multiples of 11.4x, 8.3x, and 5.8x, respectively.

Analysts’ recommendations

According to the data on November 28, 2016, Allergan’s stock value fell more than 40% over the last 12 months. Analysts estimate that the stock has the potential to return ~39.5% over the next 12 months. Analysts’ recommendations show a 12-month targeted price of $265.11 per share—compared to the last price of $189.99 per share as of November 28, 2016. Also, 78% of the analysts recommend a “buy” and 22% recommend a “hold.” Changes in analysts’ estimates and recommendations are based on changing trends in the stock price.

Investors can consider ETFs like the iShares S&P Global Health Care ETF (IXJ) in order to divest the risk. IXJ has 2.2% of its total assets in Allergan.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.